Sign In

Login

Password

Forgot Password ? Sign Up

ドスタルリマブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ドスタルリマブ" in Japanese language version.

refsWebsite
Global rank Japanese rank
17web.archive.org
1st place
1st place
8wikipedia.org
low place
low place
3clinicaltrials.gov
5,225th place
low place
3nih.gov
4th place
24th place
2europa.eu
68th place
425th place
2fda.gov
447th place
1,043rd place
2doi.org
2nd place
6th place
2gsk.com
low place
5,782nd place
1tga.gov.au
3,984th place
low place
1canada.ca
1,712th place
7,476th place
1hres.ca
low place
low place
1ama-assn.org
3,257th place
6,629th place
1prnewswire.com
406th place
1,806th place
1globenewswire.com
2,614th place
6,858th place
1anaptysbio.com
low place
low place
1cancerit.jp
low place
8,165th place
1targetedonc.com
low place
low place
1drugs.com
399th place
1,603rd place
1medscape.com
719th place
3,311th place
1handle.net
102nd place
78th place

ama-assn.org

searchusan.ama-assn.org

anaptysbio.com

ir.anaptysbio.com

canada.ca

cancerit.jp

clinicaltrials.gov

  • 臨床試験番号 NCT02715284 研究名 "A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET)" - ClinicalTrials.gov
  • 臨床試験番号 NCT03981796 研究名 "A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)" - ClinicalTrials.gov
  • 臨床試験番号 NCT03602859 研究名 "A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)" - ClinicalTrials.gov

doi.org

  • Kasherman L, Ahrari S, Lheureux S (March 2021). “Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer”. Future Oncology (London, England) 17 (8): 877–892. doi:10.2217/fon-2020-0655. PMID 33251877. 
  • Galienne M, Rodrigues M (2021). “[New drug approval: Dostarlimab – second line in advanced MSI endometrial cancer]” (French). Bulletin Du Cancer 108 (7-8): 675–676. doi:10.1016/j.bulcan.2021.04.006. PMID 33994164. 

drugs.com

europa.eu

ema.europa.eu

fda.gov

  • "FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA) (Press release). 22 April 2021. 2021年4月22日時点のオリジナルよりアーカイブ。2021年4月22日閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
  • “FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors”. U.S. Food and Drug Administration (FDA) (18 August 2021). 18 August 2021時点のオリジナルよりアーカイブ。18 August 2021閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。

globenewswire.com

gsk.com

admin-usv5.production.gsk.com

us.gsk.com

handle.net

hdl.handle.net

hres.ca

hpr-rps.hres.ca

medscape.com

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Kasherman L, Ahrari S, Lheureux S (March 2021). “Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer”. Future Oncology (London, England) 17 (8): 877–892. doi:10.2217/fon-2020-0655. PMID 33251877. 
  • Galienne M, Rodrigues M (2021). “[New drug approval: Dostarlimab – second line in advanced MSI endometrial cancer]” (French). Bulletin Du Cancer 108 (7-8): 675–676. doi:10.1016/j.bulcan.2021.04.006. PMID 33994164. 

dailymed.nlm.nih.gov

prnewswire.com

targetedonc.com

tga.gov.au

  • “Jemperli APMDS”. Therapeutic Goods Administration (TGA) (2 March 2022). 19 March 2022時点のオリジナルよりアーカイブ。5 March 2022閲覧。

web.archive.org

wikipedia.org

en.wikipedia.org

  • “Jemperli EPAR”. European Medicines Agency (EMA) (24 February 2021). 14 May 2022時点のオリジナルよりアーカイブ。16 July 2021閲覧。
  • "FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA) (Press release). 22 April 2021. 2021年4月22日時点のオリジナルよりアーカイブ。2021年4月22日閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
  • Statement On A Nonproprietary Name Adopted By The USAN Council - Dostarlimab Archived 24 September 2018 at the Wayback Machine., American Medical Association.
  • “FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors”. U.S. Food and Drug Administration (FDA) (18 August 2021). 18 August 2021時点のオリジナルよりアーカイブ。18 August 2021閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
  • 臨床試験番号 NCT02715284 研究名 "A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET)" - ClinicalTrials.gov
  • 臨床試験番号 NCT03981796 研究名 "A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)" - ClinicalTrials.gov
  • 臨床試験番号 NCT03602859 研究名 "A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)" - ClinicalTrials.gov
  • "Jemperli: Pending EC decision". European Medicines Agency (EMA) (Press release). 25 February 2021. 2021年4月23日時点のオリジナルよりアーカイブ。2021年4月22日閲覧。